Argenx Announces Discontinuation of Late-Stage Trial, Stock Drops
Argenx (ARGX) reported a significant decline in its stock price after announcing the discontinuation of a late-stage trial for an injectable version of Vyvgart. The therapy is intended to treat Sjögren's disease, an autoimmune condition. The decision came as a setback for investors who had high hopes for this new formulation of the drug. With premarket trading showing more than 14% decline in ADRs (American Depositary Receipts), market confidence appears shaken by the news. This development highlights ongoing challenges faced by biotech firms in advancing therapies through clinical trials, particularly when they involve innovative delivery methods such as injectable formulations.
Tickers: $ARGX
Topics: biotech drug development Sjögren's disease